🚨 New RCT Alert from the NEJM!
Can an old 💊 make a comeback in modern 💓 failure care?
📌 The DIGIT-HF trial showed that digitoxin, a cardiac glycoside with hepatic clearance, reduced the combined endpoint of all-cause death or HF hospitalization in HFrEF patients on contemporary guideline-directed therapy — including ARNI, beta-blockers, MRAs & SGLT2i.
🩺 HR = 0.82; p = 0.03 📉
👩⚕️ Safe in CKD, consistent benefit in women.
⚠️ Serious AEs slightly higher (4.7% vs 2.8%)
📥 NNT = 22.
💡Is it time to reconsider digitoxin in advanced HFrEF?
#CardioTwitter #HFrEF #HeartFailure #Digitoxin #NEJM #Cardiology #SGLT2i #GuidelineTherapy
